Merck Announces Multiple Myeloma Drug Trial Results
Merck announced today that a Phase III study of Zolinza ( vorinostat ), for investigational use in combination with bortezomib in patients with progressive multiple myeloma , met its primary endpoint, demonstrating a 23 percent reduction in the risk of progression compared to the standard therapy of bortezomib (p=0.01).
Getting Beyond Cancer Drug Resistance
Some cancers respond well to chemotherapy in the beginning. After some time, though, the therapy may stop working because of a condition known as acquired drug resistance (ADR). Doctors are gaining ground in understanding why this resistance happens.
Overcoming Transplant Rejection
Blood cancers - leukemia, lymphoma and myeloma - interfere with the body's ability to make healthy blood cells. Scientists may have discovered a new way to treat these diseases in ways that offer new hope.
The Risks of Rural Life
It seems so idyllic - the farm life does. Yet new research finds that children who grew up on a livestock farm are at greater risk for developing certain types of cancer.
FDA Drug Safety Communication: Revlimid
The U.S. Food and Drug Administration (FDA) is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid ( lenalidomide ) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug. FDA is currently reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review. At this time, FDA recommends that patients continue their Revlimid treatment as prescribed by their...
New Hope for Multiple Myeloma Patients
While there is no cure for multiple myeloma, a form of blood cancer, new therapy offers hope for keeping the disease from progressing. When used as a maintenance or ongoing therapy, Revlimid (lenalidomide) delays the progression of multiple myeloma and improves overall survival of newly diagnosed patients who have had a stem-cell transplant.